With the advancement of ADT, agonists and antagonists targeting gonadotropin-releasing hormone (GnRH) continuously suppress testosterone to a castration level through negative feedback on GnRH receptors (2, 3, 11, 12) GnRH therapies improve the outcomes of patients with prostate cancer, but evidence regarding the association between prostate cancer and VTEs is scarce (11, 13, 14). Here, GNRH1 is linked to prostate cancer.